Alector LLC, a San Francisco, CA-based biotech company developing immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders, raised $29.5m in a Series D financing.
The round was led by the Dementia Discovery Fund, with participation from new investors Amgen Ventures and AbbVie and existing investors Merck Research Lab Ventures, OrbiMed, Polaris Partners, GV (formerly Google Ventures), Topspin Partners and Mission Bay Capital.
Led by Arnon Rosenthal, Ph.D., co-founder, president and CEO, and Professor Tillman Gerngross, co-founder and chairman of the board, Alector Alector is a neurology-focused startup that is pioneering the discovery and development of first-in-class, immuno-modulatory therapies for Alzheimer’s disease and other neurodegenerative disorders. They are combining antibody technology and recent discoveries in neuro-immunology and human genetics to develop a broad platform of novel therapeutics that harness the immune system to fight dementia and neurodegeneration.
Alector is currently hiring immunologists and neurobiologists at all levels.